Fundraising Fox

Semma Therapeutics

acquired by Vertex Pharmaceuticals

Cambridge, US · Founded 2014 · Delaware corporation · 2 known investors

Find your way into Semma Therapeutics

Acquired by Vertex Pharmaceuticals September 2019 · $950M ($950 million in cash) · source ↗

Semma Therapeutics was a Cambridge, MA biotech that developed stem-cell-derived human pancreatic islet cells and an encapsulation device as a potential curative cell therapy for type 1 diabetes, based on research from Harvard's Douglas Melton.

Biotech

Founders & leadership

RM
Robert MillmanExecutive
KT
Kingsley TaftNamed on SEC filing

Board

TFTodd Foley
Todd FoleyinBoard directorManaging Director at MPM BioImpact
MF
Mitch FinerBoard director
SKStephen Knight
Stephen KnightinBoard directorPresident & Senior Managing Partner at F-Prime Capital Partners
JS
Jim ScopaBoard director
WS
William SahlmanBoard director

Investors · 2

F-Prime CapitalCambridge · $3M – $10M
MPM BioImpactreportedBoston · $1M – $15M

Reported raises · per SEC filings

Form D private placements

$129.3M disclosed across 2 rounds · 2015–2017

▶$113.9MraisedFeb 2019 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kingsley TaftExecutive Officer
  • Todd FoleyExecutive Officer, Director
  • Kevin RaidyDirector
  • Daniel AuerbachDirector
  • William SahlmanDirector
  • Mitchell FinerDirector
  • Mark FishmanDirector
  • Stephen KnightDirector
  • Bastiano SannaExecutive Officer, Director
Offering amount
$119.9M
Amount sold
$113.9M
First sale
Nov 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.4MraisedMar 2016 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kingsley TaftExecutive Officer
  • Todd FoleyExecutive Officer, Director
  • William SahlmanDirector
  • Mitch FinerDirector
  • Stephen KnightDirector
  • Robert MillmanExecutive Officer, Director
  • Jim ScopaDirector
Offering amount
$25M
Amount sold
$15.4M
First sale
Mar 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Semma Therapeutics raises $114M in Series B funding roundpbn.com · Dec 2017Semma scoops $114M to trial curative diabetes cell therapy | Fierce Biotechfiercebiotech.com · Nov 2017Start-up Semma Therapeutics raises 114 million dollars to beat type 1 diabetes - Diabetesdiabetes.co.uk · Nov 2017Semma Therapeutics raises $114m for novel diabetes treatment - The Boston Globebostonglobe.com · Nov 2017SEMMA THERAPEUTICS ANNOUNCES $44 MILLION IN FUNDING LED BY MPM CAPITAL TO DEVELOP CELL THERAPY FOR TREATING TYPE 1 DIABETES; SIGNS AGREEMENT WITH GLOBAL PHARMACEUTICAL COMPANY | Fierce Biotechfiercebiotech.com · Mar 2015Semma Therapeutics funding round, March 2017 - Wiki | Goldengolden.com

Frequently asked questions

What does Semma Therapeutics do?
Semma Therapeutics was a Cambridge, MA biotech that developed stem-cell-derived human pancreatic islet cells and an encapsulation device as a potential curative cell therapy for type 1 diabetes, based on research from Harvard's Douglas Melton.
Who are Semma Therapeutics's investors?
Semma Therapeutics's investors include F-Prime Capital, MPM BioImpact.
How much funding has Semma Therapeutics raised?
Semma Therapeutics has disclosed $129.3M raised across 2 rounds.
Who acquired Semma Therapeutics?
Semma Therapeutics was acquired by Vertex Pharmaceuticals.
Where is Semma Therapeutics headquartered?
Semma Therapeutics is headquartered in Cambridge, US.